KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

GoodRx Holdings (GDRX) Enterprise Value (2019 - 2025)

GoodRx Holdings' Enterprise Value history spans 7 years, with the latest figure at -$261.8 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 41.6% year-over-year to -$261.8 million; the TTM value through Dec 2025 reached -$261.8 million, up 41.6%, while the annual FY2025 figure was -$261.8 million, 41.6% up from the prior year.
  • Enterprise Value for Q4 2025 was -$261.8 million at GoodRx Holdings, up from -$273.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$261.8 million in Q4 2025 and bottomed at -$993.4 million in Q1 2021.
  • The 5-year median for Enterprise Value is -$729.7 million (2022), against an average of -$642.1 million.
  • The largest annual shift saw Enterprise Value tumbled 936.51% in 2021 before it soared 46.69% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$941.1 million in 2021, then grew by 19.55% to -$757.2 million in 2022, then increased by 11.21% to -$672.3 million in 2023, then soared by 33.31% to -$448.3 million in 2024, then soared by 41.6% to -$261.8 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Enterprise Value are -$261.8 million (Q4 2025), -$273.5 million (Q3 2025), and -$281.3 million (Q2 2025).